Evidence map›Paper›PMID 26596949›Full record

ArticleAntimicrobial agents and chemotherapy2016

Exposing a β-Lactamase "Twist": the Mechanistic Basis for the High Level of Ceftazidime Resistance in the C69F Variant of the Burkholderia pseudomallei PenI β-Lactamase.

Krisztina M Papp-Wallace, Scott A Becka, Magdalena A Taracila, Marisa L Winkler, Julian A Gatta, Drew A Rholl, Herbert P Schweizer, Robert A Bonomo

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 28 citations in OpenAlex.

  1. Antimicrobial agents and chemotherapy · 2025
    Article
  2. Article
  3. The Class A β-Lactamase Produced byAntibiotics (Basel, Switzerland) · 2022
    Article
  4. High prevalence ofAIMS microbiology · 2022
    Article
  5. Antimicrobial agents and chemotherapy · 2021
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. β-Lactamases: A Focus on Current Challenges.Cold Spring Harbor perspectives in medicine · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Krisztina M Papp-WallaceResearch Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA papp@va.gov robert.bonomo@va.gov.
Scott A BeckaResearch Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA.
Magdalena A TaracilaResearch Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Marisa L WinklerResearch Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, Ohio, USA.
Julian A GattaResearch Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA.
Drew A RhollDepartment of Biology, North Park University, Chicago, Illinois, USA.
Herbert P SchweizerDepartment of Molecular Genetics and Microbiology, College of Medicine Emerging Pathogens Institute, Institute for Therapeutic Innovation, University of Florida, Gainesville, Florida, USA.
Robert A BonomoResearch Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio, USA Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, Ohio, USA Department of Biochemistry, Case Western Reserve University, Cleveland, Ohio, USA papp@va.gov robert.bonomo@va.gov.
Case Western Reserve University · USLouis Stokes Cleveland VA Medical Center · USNorth Park University · USUniversity of Florida · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4M
Understanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9M
A Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4M
The Continuing Challenge of Carbapenemases in K. pneumoniae: KPC-2 & NDM-1I01BX001974 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI BONOMO, ROBERT A. · 2013 to 2024
–
Targeting Burkholderial β-lactamases: Structure, function, and regulationI01BX002872 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI DONSKEY, CURTIS, PAPP-WALLACE, KRISZTINA MARGARET · 2016 to 2023
–
BLRD VA I01 BX001974BLRD VA I01 BX002872NIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI100560NIAID NIH HHS U54 AI03657NIGMS NIH HHS T32 GM007250NIGMS NIH HHS T32 GM07250
6 · The paper itself

Abstract

Around the world, Burkholderia spp. are emerging as pathogens highly resistant to β-lactam antibiotics, especially ceftazidime. Clinical variants of Burkholderia pseudomallei possessing the class A β-lactamase PenI with substitutions at positions C69 and P167 are known to demonstrate ceftazidime resistance. However, the biochemical basis for ceftazidime resistance in class A β-lactamases in B. pseudomallei is largely undefined. Here, we performed site saturation mutagenesis of the C69 position and investigated the kinetic properties of the C69F variant of PenI from B. pseudomallei that results in a high level of ceftazidime resistance (2 to 64 mg/liter) when expressed in Escherichia coli. Surprisingly, quantitative immunoblotting showed that the steady-state protein levels of the C69F variant β-lactamase were ∼4-fold lower than those of wild-type PenI (0.76 fg of protein/cell versus 4.1 fg of protein/cell, respectively). However, growth in the presence of ceftazidime increases the relative amount of the C69F variant to greater than wild-type PenI levels. The C69F variant exhibits a branched kinetic mechanism for ceftazidime hydrolysis, suggesting there are two different conformations of the enzyme. When incubated with an anti-PenI antibody, one conformation of the C69F variant rapidly hydrolyzes ceftazidime and most likely contributes to the higher levels of ceftazidime resistance observed in cell-based assays. Molecular dynamics simulations suggest that the electrostatic characteristics of the oxyanion hole are altered in the C69F variant. When ceftazidime was positioned in the active site, the C69F variant is predicted to form a greater number of hydrogen-bonding interactions than PenI with ceftazidime. In conclusion, we propose "a new twist" for enhanced ceftazidime resistance mediated by the C69F variant of the PenI β-lactamase based on conformational changes in the C69F variant. Our findings explain the biochemical basis of ceftazidime resistance in B. pseudomallei, a pathogen of considerable importance, and suggest that the full repertoire of conformational states of a β-lactamase profoundly affects β-lactam resistance.

Indexed as

Anti-Bacterial Agentsbeta-Lactamasesbeta-Lactam ResistanceBurkholderia pseudomalleiCatalytic DomainCeftazidimeCrystallography, X-RayEscherichia coliMicrobial Sensitivity TestsMolecular Dynamics SimulationMutagenesis, Site-DirectedProtein ConformationAnti-Bacterial Agentsbeta-LactamasesCeftazidime

Identifiers

PMID26596949
PMCPMC4750712
OpenAlexW2179733851

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.